The CDC5L antibody targets the Cell Division Cycle 5-Like (CDC5L) protein, a conserved component of the PRP19 complex involved in pre-mRNA splicing and DNA repair. CDC5L plays critical roles in cell cycle progression, particularly during the G2/M phase transition and mitotic exit. It interacts with other spliceosome-associated proteins to regulate the assembly and catalytic activation of the spliceosome, ensuring accurate mRNA processing. Dysregulation of CDC5L is linked to genomic instability, cancer progression, and developmental disorders. Antibodies against CDC5L are widely used in research to study its expression, localization, and molecular interactions via techniques like Western blotting, immunofluorescence, and immunoprecipitation. These tools help elucidate CDC5L's functional mechanisms in splicing regulation, cell cycle control, and DNA damage responses. Commercial CDC5L antibodies are typically raised in rabbits or mice, with validation in human, mouse, or rat samples. Researchers utilize these reagents to investigate CDC5L's involvement in diseases, including its overexpression in certain cancers and potential as a therapeutic target. Proper validation through knockout controls or siRNA knockdown is essential due to potential cross-reactivity with related proteins.